Site intended for healthcare professionals only
Lung cancer screening (LCS) using low-dose computed tomography (LDCT) is recommended for people at high risk of dying from lung cancer. Communication strategies for clinicians have been recommended but their […]
» Read moreThere has been limited evidence for the association between chronic obstructive pulmonary disease (COPD) and the incidence of lung cancer among never smokers. We aimed to estimate the risk of […]
» Read moreDysregulation of receptor tyrosine kinase MET by various mechanisms occurs in 3-4% of NSCLC and is associated with unfavorable prognosis. While MET is a validated drug target in lung cancer […]
» Read moreFew options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic transcription. In this phase 2 study, […]
» Read moreThe European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) assesses quality of life (QOL) in patients with lung cancer and was the […]
» Read moreIn PACIFIC, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, Stage III NSCLC patients without progression after chemoradiotherapy (CRT). We report exploratory analyses […]
» Read moreMany patients with metastatic non-small-cell lung cancer (mNSCLC) experience disease progression after first- and second-line treatment; more treatment options are required for these patients. ARCTIC, a phase III, randomized, open-label […]
» Read moreTherapeutic blockade of the axis of programmed cell death 1 (PD-1) and its ligand (PD-L1) has transformed the management of non-small-cell lung cancer (NSCLC). Clinical trials with pembrolizumab have enrolled […]
» Read moreProgrammed cell death ligand 1 (PD-L1) tumor proportion score (TPS) is the primary clinically-available biomarker of response to immunotherapy in non-small cell lung cancer (NSCLC), but factors associated with PD-L1 […]
» Read moreWith increasingly precise radiotherapy and advanced medical imaging, the concept of radiotherapy target volume planning might be redefined with the aim of improving outcomes. We aimed to investigate whether target […]
» Read moreIn KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective […]
» Read moreOsimertinib is a potent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study (NCT02143466) was designed to assess the safety and tolerability of […]
» Read moreWe report a primary care-based lung cancer targeted screening programme using low-dose CT (LDCT) in South Tyneside and Sunderland. Ever smokers with ≥10 pack-years aged 55-74 years were identified at […]
» Read morePreclinical data have shown that proton pump inhibitors (PPI) can modulate the microbiome, and single-arm studies suggested that antibiotics (ATB) may decrease the efficacy of immune checkpoint inhibitors (ICI), but […]
» Read moreIn the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing advanced non‒small-cell lung cancer (NSCLC) in patients with a tumor proportion score […]
» Read moreImmune checkpoint inhibitors (ICIs) are standard therapies for patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. Tumor mutation burden (TMB) […]
» Read moreIn Europe, lung cancer ranks third among the most common cancers, remaining the biggest killer. Since the publication of the first European Society of Radiology and European Respiratory Society joint […]
» Read morePembrolizumab plus pemetrexed-platinum led to superior overall survival and progression-free survival, and a higher proportion of patients with a confirmed complete or partial response over placebo plus pemetrexed-platinum in the […]
» Read moreLung cancer screening-despite its proven mortality benefit-remains vastly underutilized. Prior studies examined knowledge, attitudes, and beliefs to better understand the reasons underlying low screening rates. These investigations may have limited […]
» Read moreClick here to read the full article @ European heart journal Subscribe to ClinOwl to get the latest clinical articles tailored to your interests
» Read morePreclinical data suggest that EGFR tyrosine kinase inhibitors (TKIs) plus MET TKIs are a possible treatment for EGFR mutation-positive lung cancers with MET-driven acquired resistance. Phase 1 safety data of […]
» Read moreClick here to read the full article @ The Lancet. Oncology Subscribe to ClinOwl email updates and receive the latest articles tailored to your specialty
» Read moreVarious risk factors for depression in lung cancer patients have been suggested but have been examined separately in studies with relatively small sample sizes. The present study examined the biopsychosocial […]
» Read moreA number of epidemiological studies have reported inconsistent findings on the association between meat consumption and lung cancer.We therefore conducted a systematic review and meta-analysis to investigate the relationship between […]
» Read moreTecemotide is a MUC1-antigen-specific cancer immunotherapy. The phase III START study did not meet its primary end point but reported notable survival benefit with tecemotide versus placebo in an exploratory […]
» Read moreWe investigated the efficacy of irinotecan/cisplatin (IP) versus irinotecan/capecitabine (IX) with or without isosorbide-5-mononitrate (ISMN) in chemo-naïve advanced non-small-cell lung cancer.Initially, 74 patients were randomly assigned to either IP or […]
» Read more